(Q37966063)

26 August 2017

title

HDL-C: role as a risk modifier (English)

1 reference

26 August 2017

Philip Barter

1

1 reference

26 August 2017

publication date

1 November 2011

1 reference

Atherosclerosis. Supplements

26 August 2017

published in

1 reference

26 August 2017

volume

12

1 reference

26 August 2017

issue

3

1 reference

26 August 2017

page(s)

267-270

1 reference

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2811%2970885-6

7 January 2021

Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2811%2970885-6

7 January 2021

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2811%2970885-6

7 January 2021

European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by rep

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2811%2970885-6

7 January 2021

2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2811%2970885-6

7 January 2021

ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2811%2970885-6

7 January 2021

Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2811%2970885-6

7 January 2021

Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2811%2970885-6

7 January 2021

The epidemiology of low levels of high-density lipoprotein cholesterol in patients with and without coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2811%2970885-6

7 January 2021

HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2811%2970885-6

7 January 2021

Major lipids, apolipoproteins, and risk of vascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2811%2970885-6

7 January 2021

Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2811%2970885-6

7 January 2021

The Tangier disease gene product ABC1 controls the cellular apolipoprotein-mediated lipid removal pathway

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2811%2970885-6

7 January 2021

Effect of statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis of the VOYAGER Database

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2811%2970885-6

7 January 2021

Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk.

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2811%2970885-6

7 January 2021

Meta-analysis of comparative efficacy of increasing dose of Atorvastatin versus Rosuvastatin versus Simvastatin on lowering levels of atherogenic lipids (from VOYAGER).

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2811%2970885-6

7 January 2021

Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2811%2970885-6

7 January 2021

The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL.

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2811%2970885-6

7 January 2021

Antiinflammatory properties of HDL.

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2811%2970885-6

7 January 2021

Endothelial and antithrombotic actions of HDL.

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2811%2970885-6

7 January 2021

High-density lipoproteins enhance progenitor-mediated endothelium repair in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2811%2970885-6

7 January 2021

High-density lipoprotein modulates glucose metabolism in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2811%2970885-6

7 January 2021

Effects of high-density lipoproteins on pancreatic beta-cell insulin secretion

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2811%2970885-6

7 January 2021

Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI.

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2811%2970885-6

7 January 2021

Apolipoprotein AI transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2811%2970885-6

7 January 2021

High-density lipoproteins retard the progression of atherosclerosis and favorably remodel lesions without suppressing indices of inflammation or oxidation

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2811%2970885-6

7 January 2021

Elevating high-density lipoprotein cholesterol in apolipoprotein E-deficient mice remodels advanced atherosclerotic lesions by decreasing macrophage and increasing smooth muscle cell content

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2811%2970885-6

7 January 2021

High-dose recombinant apolipoprotein A-I(milano) mobilizes tissue cholesterol and rapidly reduces plaque lipid and macrophage content in apolipoprotein e-deficient mice. Potential implications for acute plaque stabilization

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2811%2970885-6

7 January 2021

Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2811%2970885-6

7 January 2021

Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2811%2970885-6

7 January 2021

Statins, High-Density Lipoprotein Cholesterol, and Regression of Coronary Atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2811%2970885-6

7 January 2021

Evaluating the incremental benefits of raising high-density lipoprotein cholesterol levels during lipid therapy after adjustment for the reductions in other blood lipid levels

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2811%2970885-6

7 January 2021

10.1016/S1567-5688(11)70885-6

Identifiers

DOI

1 reference

26 August 2017

1 reference